You are here

Keller, Charles MD & Langenau, David PhD

Charles Keller, MD
Children's Cancer Therapy Development Institute
Award Years: 2013 & 2014
Project title: GSK3-beta inhibitors for relapsed rhabdomyosarcoma - Co-Leader

Dr. Charles Keller's research focuses on the development of more effective, less toxic therapies for childhood cancers. His special interest is advanced disease that has spread beyond the initial location of the cancer. Dr. Keller co-chairs the brain tumor developmental therapeutics committee (CNS-DVL) of the Children’s Oncology Group and is a member of the soft tissue sarcoma (STS) committee of Children’s Oncology Group, and recently completed a 5-year rotation as a Standing Member of the National Cancer Institute NCI-I Study Section.


David Langenau, PhD
Massachusetts General Hospital
Award Years: 2013 & 2014
Project title: GSK3-beta inhibitors for relapsed rhabdomyosarcoma - Co-Leader

Dr. David Langenau is Assistant Pathologist at the Massachusetts General Hospital, and Associate Professor of Pathology at the Harvard Medical School. His research interests include identifying the genetic programs underlying self-renewal  rhabdomyosarcoma cancer stem cells and uncovering self-renewal programs in T-cell acute lymphoblastic leukemia.